JP2020073481A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020073481A5 JP2020073481A5 JP2019192289A JP2019192289A JP2020073481A5 JP 2020073481 A5 JP2020073481 A5 JP 2020073481A5 JP 2019192289 A JP2019192289 A JP 2019192289A JP 2019192289 A JP2019192289 A JP 2019192289A JP 2020073481 A5 JP2020073481 A5 JP 2020073481A5
- Authority
- JP
- Japan
- Prior art keywords
- product according
- beta
- peptide product
- substituted
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 32
- -1 1-eicosyl beta-D-glucuronic acid Chemical group 0.000 claims 21
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 239000004094 surface-active agent Substances 0.000 claims 9
- 239000002253 acid Substances 0.000 claims 7
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 125000006239 protecting group Chemical group 0.000 claims 4
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 claims 3
- 125000004171 alkoxy aryl group Chemical group 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 150000003431 steroids Chemical class 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 229930182470 glycoside Natural products 0.000 claims 2
- CLRWZDLKTLJVEF-ZXPJVPCYSA-N (2s,3s,4s,5r,6r)-3,4,5,6-tetrahydroxy-6-octyloxane-2-carboxylic acid Chemical group CCCCCCCC[C@@]1(O)O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O CLRWZDLKTLJVEF-ZXPJVPCYSA-N 0.000 claims 1
- KZPCPTBVXOXXOY-GRYWWWGRSA-N (2s,3s,4s,5r,6r)-6-decyl-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical group CCCCCCCCCC[C@@]1(O)O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O KZPCPTBVXOXXOY-GRYWWWGRSA-N 0.000 claims 1
- SHCMCJLNUOZJOR-YXISZKLHSA-N (2s,3s,4s,5r,6r)-6-dodecyl-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical group CCCCCCCCCCCC[C@@]1(O)O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O SHCMCJLNUOZJOR-YXISZKLHSA-N 0.000 claims 1
- 102000051325 Glucagon Human genes 0.000 claims 1
- 108060003199 Glucagon Proteins 0.000 claims 1
- 108091016366 Histone-lysine N-methyltransferase EHMT1 Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- SCIFESDRCALIIM-VIFPVBQESA-N N-methyl-L-phenylalanine Chemical compound C[NH2+][C@H](C([O-])=O)CC1=CC=CC=C1 SCIFESDRCALIIM-VIFPVBQESA-N 0.000 claims 1
- 102100040918 Pro-glucagon Human genes 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical group C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 1
- 229960004666 glucagon Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000017854 proteolysis Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022005872A JP7389150B2 (ja) | 2011-05-18 | 2022-01-18 | インスリン抵抗性のための改善されたペプチドの調合薬 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161487640P | 2011-05-18 | 2011-05-18 | |
| US61/487,640 | 2011-05-18 | ||
| US201161543716P | 2011-10-05 | 2011-10-05 | |
| US61/543,716 | 2011-10-05 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017028560A Division JP6684396B2 (ja) | 2011-05-18 | 2017-02-19 | インスリン抵抗性のための改善されたペプチドの調合薬 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022005872A Division JP7389150B2 (ja) | 2011-05-18 | 2022-01-18 | インスリン抵抗性のための改善されたペプチドの調合薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020073481A JP2020073481A (ja) | 2020-05-14 |
| JP2020073481A5 true JP2020073481A5 (enExample) | 2020-06-25 |
| JP7015610B2 JP7015610B2 (ja) | 2022-02-15 |
Family
ID=47177642
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014511554A Active JP6284471B2 (ja) | 2011-05-18 | 2012-05-17 | インスリン抵抗性のための改善されたペプチドの調合薬 |
| JP2017028560A Active JP6684396B2 (ja) | 2011-05-18 | 2017-02-19 | インスリン抵抗性のための改善されたペプチドの調合薬 |
| JP2019192289A Active JP7015610B2 (ja) | 2011-05-18 | 2019-10-21 | インスリン抵抗性のための改善されたペプチドの調合薬 |
| JP2022005872A Active JP7389150B2 (ja) | 2011-05-18 | 2022-01-18 | インスリン抵抗性のための改善されたペプチドの調合薬 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014511554A Active JP6284471B2 (ja) | 2011-05-18 | 2012-05-17 | インスリン抵抗性のための改善されたペプチドの調合薬 |
| JP2017028560A Active JP6684396B2 (ja) | 2011-05-18 | 2017-02-19 | インスリン抵抗性のための改善されたペプチドの調合薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022005872A Active JP7389150B2 (ja) | 2011-05-18 | 2022-01-18 | インスリン抵抗性のための改善されたペプチドの調合薬 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10471127B2 (enExample) |
| EP (1) | EP2710031B9 (enExample) |
| JP (4) | JP6284471B2 (enExample) |
| KR (5) | KR20230023059A (enExample) |
| CN (2) | CN111701028A (enExample) |
| AU (1) | AU2012255119B2 (enExample) |
| BR (1) | BR112013029409B1 (enExample) |
| CA (2) | CA2836574C (enExample) |
| DK (1) | DK2710031T3 (enExample) |
| IL (1) | IL229373B (enExample) |
| MX (1) | MX344219B (enExample) |
| RU (1) | RU2602801C2 (enExample) |
| WO (1) | WO2012158965A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2295452A1 (en) | 2005-05-04 | 2011-03-16 | Zealand Pharma A/S | Glucagon-like-peptide-2 (GLP-2) analogues |
| US8642727B2 (en) | 2006-11-08 | 2014-02-04 | Zealand Pharma A/S | Selective glucagon-like-peptide-2 (GLP-2) analogues |
| EP4286400A3 (en) | 2011-05-18 | 2024-06-05 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| KR20230023059A (ko) | 2011-05-18 | 2023-02-16 | 메더리스 다이어비티즈, 엘엘씨 | 인슐린 저항성에 대한 개선된 펩티드 제약 |
| BR112014006684A2 (pt) | 2011-09-23 | 2017-03-28 | Novo Nordisk As | análogos de glucagon |
| AU2013255752B2 (en) * | 2012-05-03 | 2017-11-09 | Zealand Pharma A/S | Glucagon-like-peptide-2 (GLP-2) analogues |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| EP3444281B1 (en) * | 2012-11-20 | 2021-11-03 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| CN104918961A (zh) | 2012-11-20 | 2015-09-16 | 梅德瑞斯糖尿病有限责任公司 | 用于胰岛素抗性的改良的肽药物 |
| EP2934568B1 (en) | 2012-12-21 | 2017-10-18 | Sanofi | Dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| WO2014170496A1 (en) | 2013-04-18 | 2014-10-23 | Novo Nordisk A/S | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
| EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| CN106661097A (zh) * | 2014-05-28 | 2017-05-10 | 梅德瑞斯糖尿病有限责任公司 | 针对胰岛素抵抗的改良肽药物 |
| JP2017525656A (ja) | 2014-06-04 | 2017-09-07 | ノヴォ ノルディスク アー／エス | 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| EP3575314B1 (en) | 2014-12-30 | 2024-02-14 | Hanmi Pharm. Co., Ltd. | Glucagon derivative |
| WO2016172183A1 (en) * | 2015-04-21 | 2016-10-27 | Ran Biotechnologies, Inc. | Novel fluorinated surfactants |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| WO2016198628A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| MA49545B1 (fr) | 2015-06-30 | 2022-03-31 | Hanmi Pharm Ind Co Ltd | Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| CN115920077B (zh) | 2015-12-31 | 2025-07-04 | 韩美药品株式会社 | 胰高血糖素/glp-1/gip受体三重激动剂的长效缀合物 |
| CA3029518A1 (en) * | 2016-06-29 | 2018-01-04 | Hanmi Pharm. Co., Ltd. | Glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof |
| AU2017371516C1 (en) | 2016-12-09 | 2021-09-02 | Zealand Pharma A/S | Acylated GLP-1/GLP-2 dual agonists |
| TWI791539B (zh) | 2017-06-16 | 2023-02-11 | 丹麥商西蘭製藥公司 | 用於投予類升糖素胜肽-2(glp-2)類似物的給藥方案 |
| CN108054388B (zh) * | 2017-12-26 | 2020-02-21 | 吉林大学 | 以h6p2w18/l-3-(2-萘基)-丙氨酸复合水基黏合剂为电极涂层的化学电池 |
| HUE069178T2 (hu) | 2018-01-03 | 2025-02-28 | Mederis Diabetes Llc | Javított peptidgyógyszerek NASH és egyéb rendellenességek kezelésére |
| CN117202924A (zh) | 2020-12-07 | 2023-12-08 | 斯皮特弗尔制药有限责任公司 | 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法 |
| KR20240007251A (ko) | 2021-05-13 | 2024-01-16 | 카모트 테라퓨틱스, 인크. | G-단백질 결합 수용체의 조절제 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5661130A (en) | 1993-06-24 | 1997-08-26 | The Uab Research Foundation | Absorption enhancers for drug administration |
| JPH1160598A (ja) | 1997-08-15 | 1999-03-02 | Asahi Glass Co Ltd | オピオイド様ペプチド |
| US6924264B1 (en) | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| RU2181729C1 (ru) | 2000-09-20 | 2002-04-27 | Калюжин Олег Витальевич | Производные мурамовой кислоты |
| US6858580B2 (en) | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6835802B2 (en) | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
| US6864069B2 (en) * | 2001-10-05 | 2005-03-08 | Bayer Pharmaceuticals Corporation | Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
| EP2305313B1 (en) | 2001-10-10 | 2014-03-26 | ratiopharm GmbH | Remodelling and glycoconjugation of interferon-alpha (IFNa) |
| US6881829B2 (en) | 2002-04-26 | 2005-04-19 | Chimeracom, L.L.C. | Chimeric hybrid analgesics |
| US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| US20110257096A1 (en) | 2004-08-25 | 2011-10-20 | Aegis Therapeutics, Inc. | Compositions for drug administration |
| ITRM20040607A1 (it) | 2004-12-15 | 2005-03-15 | Biogen S R L | Analoghi della dermorfina ad attivita' analgesica. |
| WO2006096426A2 (en) | 2005-03-03 | 2006-09-14 | The Board Of Trustees Of The University Of Illinois | Targeted drug delivery of pain and addiction therapies using opioid receptor-mediated internalization |
| EP1883419A4 (en) | 2005-05-06 | 2010-08-04 | Bayer Pharmaceuticals Corp | GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL USES |
| WO2007002465A2 (en) | 2005-06-23 | 2007-01-04 | Rapid Pharmaceuticals, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| WO2007060692A2 (en) | 2005-11-24 | 2007-05-31 | Brain N' Beyond Biotech Pvt. Ltd. | Compositions for increasing bioavailability of peptides or proteins and method thereof |
| US8173594B2 (en) | 2006-06-23 | 2012-05-08 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| US7998927B2 (en) | 2006-06-23 | 2011-08-16 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| EP2068907B1 (en) * | 2006-10-04 | 2017-11-29 | Novo Nordisk A/S | Glycerol linked pegylated sugars and glycopeptides |
| WO2009155258A2 (en) * | 2008-06-17 | 2009-12-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| EP4286400A3 (en) | 2011-05-18 | 2024-06-05 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| KR20230023059A (ko) | 2011-05-18 | 2023-02-16 | 메더리스 다이어비티즈, 엘엘씨 | 인슐린 저항성에 대한 개선된 펩티드 제약 |
| CN104918961A (zh) | 2012-11-20 | 2015-09-16 | 梅德瑞斯糖尿病有限责任公司 | 用于胰岛素抗性的改良的肽药物 |
| EP3444281B1 (en) * | 2012-11-20 | 2021-11-03 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| CN106661097A (zh) | 2014-05-28 | 2017-05-10 | 梅德瑞斯糖尿病有限责任公司 | 针对胰岛素抵抗的改良肽药物 |
-
2012
- 2012-05-17 KR KR1020237004115A patent/KR20230023059A/ko not_active Ceased
- 2012-05-17 CA CA2836574A patent/CA2836574C/en active Active
- 2012-05-17 US US14/118,545 patent/US10471127B2/en active Active
- 2012-05-17 CA CA3134906A patent/CA3134906A1/en active Pending
- 2012-05-17 WO PCT/US2012/038434 patent/WO2012158965A2/en not_active Ceased
- 2012-05-17 BR BR112013029409-4A patent/BR112013029409B1/pt active IP Right Grant
- 2012-05-17 DK DK12785861.1T patent/DK2710031T3/en active
- 2012-05-17 CN CN202010611969.8A patent/CN111701028A/zh active Pending
- 2012-05-17 RU RU2013154047/04A patent/RU2602801C2/ru active
- 2012-05-17 EP EP12785861.1A patent/EP2710031B9/en active Active
- 2012-05-17 KR KR1020217014931A patent/KR102497726B1/ko active Active
- 2012-05-17 JP JP2014511554A patent/JP6284471B2/ja active Active
- 2012-05-17 MX MX2013013395A patent/MX344219B/es active IP Right Grant
- 2012-05-17 CN CN201280035629.9A patent/CN103732617A/zh active Pending
- 2012-05-17 KR KR1020137033668A patent/KR102011924B1/ko active Active
- 2012-05-17 KR KR1020247021588A patent/KR20240110072A/ko active Pending
- 2012-05-17 AU AU2012255119A patent/AU2012255119B2/en active Active
- 2012-05-17 KR KR1020197023482A patent/KR102255479B1/ko active Active
-
2013
- 2013-11-11 IL IL229373A patent/IL229373B/en active IP Right Grant
-
2017
- 2017-02-19 JP JP2017028560A patent/JP6684396B2/ja active Active
-
2019
- 2019-10-21 JP JP2019192289A patent/JP7015610B2/ja active Active
-
2022
- 2022-01-18 JP JP2022005872A patent/JP7389150B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020073481A5 (enExample) | ||
| JP2016501204A5 (enExample) | ||
| JP2014516037A5 (enExample) | ||
| JP2020143066A5 (enExample) | ||
| DE69426206T2 (de) | Verbindungen mit wachstumshormonfreisetzenden eigenschaften | |
| ES2335827T3 (es) | Analogos peptidos de pacap. | |
| US6544949B1 (en) | Analogs of parathyroid hormone | |
| KR102812908B1 (ko) | 인크레틴 유사체의 제조 방법 | |
| US20070299009A1 (en) | Analogs of parathyroid hormone | |
| AU636301B2 (en) | Cyclic grf-analogs ii | |
| KR950702578A (ko) | 파라티로이드 호르몬(pth) 및 파라티로이드 호르몬 관련 펩티드(pthrp)의 유사체, 이들의 합성 및 골다공증 치료를 위한 이들의 용도(analogs of pth and pthrp, their synthesis and use for the treatment of osteoporosis) | |
| KR20110125235A (ko) | 뉴로펩타이드 ｙ 수용체 결합성 화합물을 포함하는 세포독성 접합체 | |
| RU98117915A (ru) | Использование фармацевтической композиции, содержащей пептид, подавляющий аппетит | |
| RU2013154047A (ru) | Пептидные лекарственные препараты с повышенной эффективностью против инсулинорезистентности | |
| CN102702330A (zh) | 环状核心序列与生物素或穿膜肽相连而成的促黑激素类似物 | |
| EP0564588B1 (en) | Hexapeptide anaphylatoxin-receptor ligands | |
| JPH0680079B2 (ja) | ポリペプチド | |
| WO1990009162A2 (en) | Anaphylatoxin-receptor ligands | |
| JP2837352B2 (ja) | 胃腸運動活性を抑制するモチリン類似ポリペプチド | |
| JPH0273100A (ja) | 医薬用化合物 | |
| WO1996022305A2 (en) | Modified peptides | |
| EP0564533A1 (en) | Modified penta- and hexapeptide anaphylatoxin receptor ligands | |
| JPH0338600A (ja) | Ｖｉｐ同族体 | |
| WO1989010935A1 (en) | Atrial peptide derivatives | |
| US6426330B1 (en) | Satiety inducing composition comprising Neuropeptide Y analogues and methods of inducing satiety and treating a disease or condition associated with it |